Market Research Logo

Endometriosis - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsight’s ‘Endometriosis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Endometriosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Endometriosis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Endometriosis - Disease Understanding and Treatment Algorithm
The DelveInsight Endometriosis market report gives the thorough understanding of the Endometriosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Endometriosis in the US, Europe, and Japan.
Endometriosis Epidemiology
The Endometriosis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by total prevalence, diagnosed population and treatable cases of Endometriosis in 7MM.
According to DelveInsight, the prevalent cases of Endometriosis in 7 major markets was 13.8 Million in 2016 and, is expected to increase at a significant growth rate during the study period i.e., 2016-2027. Among 7MM United States account for highest incident population of Endometriosis i.e., 7.4 Million followed by United Kingdom.

Endometriosis Drug Chapters
This segment of the Endometriosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline products. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The marketed drugs available for the treatment of Endometriosis mainly include Lupron (Abbvie), Visanne/Dienogest (Bayer Healthcare), Zoladex (AstraZeneca), Synarel (Pfizer) and Depo-SubQ. Detailed chapters for all of these drugs, along with the promising upcoming therapies such as Elagolix (Abbvie), Femitra (Endooceutics) etc. have been covered in the report.

Endometriosis Market Outlook
The Endometriosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market [that includes 7MM, Rest of Europe (RoE) and Rest of World (RoW)] of Endometriosis was USD 1,856 Million in 2016, and is expected to increase at a significant growth during the study period i.e., 2016-2027.

Endometriosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Endometriosis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Endometriosis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Endometriosis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Endometriosis market
• Organize sales and marketing efforts by identifying the best opportunities for Endometriosis market
• To understand the future market competition in the Endometriosis market.


1. Report Introduction
2. Endometriosis Market Overview at a Glance
2.1. Global Market Size of Endometriosis in 2016
2.2. Global Market Size of Endometriosis in 2027
3. Disease Background and Overview: Endometriosis
3.1. Introduction
3.2. Stages
3.3. Types
3.4. Pathophysiology
3.5. Risk Factors
3.6. Diagnosis
3.7. Treatment
3.7.1. Laparoscopy
3.7.2. Laparotomy
3.7.3. Hysterectomy
4. Epidemiology of Endometriosis in 7MM
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. United States
4.3.1. Prevalent Cases of Endometriosis in the US (2016-2027)
4.3.2. Diagnosed population of Endometriosis in the US (2016-2027)
4.3.3. Treatable cases of Endometriosis in the US (2016-2027)
4.4. EU5
4.4.1. United Kingdom
4.4.1.1. Prevalent Cases of Endometriosis in the UK (2016-2027)
4.4.1.2. Diagnosed population of Endometriosis in the UK (2016-2027)
4.4.1.3. Treatable cases of Endometriosis in the UK (2016-2027)
4.4.2. Germany
4.4.2.1. Prevalent Cases of Endometriosis in Germany (2016-2027)
4.4.2.2. Diagnosed population of Endometriosis in Germany (2016-2027)
4.4.2.3. Treatable cases of Endometriosis in Germany (2016-2027)
4.4.3. France
4.4.3.1. Prevalent Cases of Endometriosis in Germany (2016-2027)
4.4.3.2. Diagnosed population of Endometriosis in Germany (2016-2027)
4.4.3.3. Treatable cases of Endometriosis in Germany (2016-2027)
4.4.4. Italy
4.4.4.1. Prevalent Cases of Endometriosis in Germany (2016-2027)
4.4.4.2. Diagnosed population of Endometriosis in Germany (2016-2027)
4.4.4.3. Treatable cases of Endometriosis in Germany (2016-2027)
4.4.5. Spain
4.4.5.1. Prevalent Cases of Endometriosis in Germany (2016-2027)
4.4.5.2. Diagnosed population of Endometriosis in Germany (2016-2027)
4.4.5.3. Treatable cases of Endometriosis in Germany (2016-2027)
4.5. Japan
4.5.1. Prevalent Cases of Endometriosis in Germany (2016-2027)
4.5.2. Diagnosed population of Endometriosis in Germany (2016-2027)
4.5.3. Treatable cases of Endometriosis in Germany (2016-2027)
5. Treatment Algorithm
5.1. Initial Treatment
5.2. Treatment of Recurrent Endometriosis
5.3. Add-Back Therapy
6. Current Unmet Needs
7. Marketed Drugs
7.1. Lupron (leuprolide acetate depot)
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages and Disadvantages
7.1.4. Product Profile
7.2. Depo-SubQ Provera 104
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages and Disadvantages
7.2.4. Product Profile
7.3. Visanne
7.3.1. Description
7.3.2. Regulatory Milestones
7.3.3. Advantages and Disadvantages
7.3.4. Product Profile
7.4. Zoladex
7.4.1. Description
7.4.2. Regulatory Milestones
7.4.3. Advantages and Disadvantages
7.4.4. Product Profile
7.5. Synarel (nafarelin nasal spray)
7.5.1. Description
7.5.2. Regulatory Milestones
7.5.3. Advantages and Disadvantages
7.5.4. Product Profile
7.6. Pamorelin/Decapeptyl/Trelstar
7.6.1. Description
7.6.2. Regulatory Milestones
7.6.3. Advantages and Disadvantages
7.6.4. Product Profile
8. Emerging Therapies
8.1. Elagolix: AbbVie Inc
8.1.1. Description
8.1.2. Regulatory Milestones
8.1.3. Clinical Development
8.1.4. Product Profile
8.1.5. Clinical Trial by Phase
8.1.6. Safety and Efficacy
8.2. Femitra: EndoCeutics Inc
8.2.1. Description
8.2.2. Regulatory Milestones
8.2.3. Clinical Development
8.2.4. Product Profile
8.2.5. Clinical Trial by Phase
8.2.6. Safety and Efficacy
8.3. BAY 86-5300: Bayer HealthCare Pharmaceuticals
8.3.1. Description
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Trial by Phase
9. Global Endometriosis: Country-Wise Market Analysis
9.1. Total Market Size of Endometriosis in 7MM (2016-2027)
9.2. Market Size by Therapy in 7MM (2016-2027)
9.3. United States Market Size
9.3.1.1. Total Market Size of Endometriosis
9.3.1.2. Market Size by Therapy
9.4. EU5
9.4.1. United Kingdom Market Size
9.4.1.1. Total Market Size of Endometriosis
9.4.1.2. Market Size by Therapy
9.4.2. Germany Market Size
9.4.2.1. Total Market Size of Endometriosis
9.4.2.2. Market Size by Therapy
9.4.3. France Market Size
9.4.3.1. Total Market Size of Endometriosis
9.4.3.2. Market Size by Therapy
9.4.4. Italy Market Size
9.4.4.1. Total Market Size of Endometriosis
9.4.4.2. Market Size by Therapy
9.4.5. Spain Market Size
9.4.5.1. Total Market Size of Endometriosis
9.4.5.2. Market Size by Therapy
9.5. Japan Market Size
9.5.1. Total Market Size of Endometriosis
9.5.2. Market Size by Therapy
10. Market Drivers
11. Market Barriers
12. Appendix
13. Report Methodology
13.1. Sources Used
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
Table 1 : Prevalent Cases of Endometriosis in United States (2016-2027)
Table 2 : Diagnosed Population of Endometriosis in United States (2016-2027)
Table 3 : Treatable Cases of Endometriosis in United States (2016-2027)
Table 4 : Prevalent Cases of Endometriosis in Germany (2016-2027)
Table 5 : Diagnosed Population of Endometriosis in Germany (2016-2027)
Table 6 : Treatable Cases of Endometriosis in Germany (2016-2027)
Table 7 : Prevalent Cases of Endometriosis in France (2016-2027)
Table 8 : Diagnosed Population of Endometriosis in France (2016-2027)
Table 9 : Treatable Cases of Endometriosis in France (2016-2027)
Table 10 : Prevalent Cases of Endometriosis in Italy (2016-2027)
Table 11 : Diagnosed Population of Endometriosis in Italy (2016-2027)
Table 12 : Treatable Cases of Endometriosis in Italy (2016-2027)
Table 13 : Prevalent Cases of Endometriosis in Spain (2016-2027)
Table 14 : Diagnosed Population of Endometriosis in Spain (2016-2027)
Table 15 : Treatable Cases of Endometriosis in Spain (2016-2027)
Table 16 : Prevalent Cases of Endometriosis in United Kingdom (2016-2027)
Table 17 : Diagnosed Population of Endometriosis in United Kingdom (2016-2027)
Table 18 : Treatable Cases of Endometriosis in United Kingdom (2016-2027)
Table 19 : Prevalent Cases of Endometriosis in Japan (2016-2027)
Table 20 : Diagnosed Population of Endometriosis in Japan (2016-2027)
Table 21 : Treatable Cases of Endometriosis in Japan (2016-2027)
Table 22 : Elagolix, Clinical Trials by Recruitment status, 2018
Table 23 : Elagolix, Clinical Trials by Zone, 2018
Table 24 : Femitra, Clinical Trials by Recruitment status, 2018
Table 25 : Femitra, Clinical Trials by Zone, 2018
Table 26 : Total 7 Major Market Size in USD, Million (2016-2027)
Table 27 : Region wise Market Size) in USD, Million (2016-2027)
Table 28 : 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 29 : United States Market Size in USD, Million (2016-2027)
Table 30 : United States Market Size by Therapy in USD, Million (2016-2027)
Table 31 : Germany Market Size in USD, Million (2016-2027)
Table 32 : Germany Market Size by Therapy in USD, Million (2016-2027)
Table 33 : France Market Size in USD, Million (2016-2027)
Table 34 : France Market Size by Therapy in USD, Million (2016-2027)
Table 35 : United Kingdom Market Size in USD, Million (2016-2027)
Table 36 : United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 37 : Spain Market Size in USD, Million (2016-2027)
Table 38 : Spain Market Size by Therapy in USD, Million (2016-2027)
Table 39 : Italy Market Size in USD, Million (2016-2027)
Table 40 : Italy Market Size by Therapy in USD, Million (2016-2027)
Table 41 : Japan Market Size in USD, Million (2016-2027)
Table 42 : Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 1 : Prevalent Cases of Endometriosis in United States (2016-2027)
Figure 2 : Diagnosed Population of Endometriosis in United States (2016-2027)
Figure 3 : Treatable Cases of Endometriosis in United States (2016-2027)
Figure 4 : Prevalent Cases of Endometriosis in Germany (2016-2027)
Figure 5 : Diagnosed Population of Endometriosis in Germany (2016-2027)
Figure 6 : Treatable Cases of Endometriosis in Germany (2016-2027)
Figure 7 : Prevalent Cases of Endometriosis in France (2016-2027)
Figure 8 : Diagnosed Population of Endometriosis in France (2016-2027)
Figure 9 : Treatable Cases of Endometriosis in France (2016-2027)
Figure 10 : Prevalent Cases of Endometriosis in Italy (2016-2027)
Figure 11 : Diagnosed Population of Endometriosis in Italy (2016-2027)
Figure 12 : Treatable Cases of Endometriosis in Italy (2016-2027)
Figure 13 : Prevalent Cases of Endometriosis in Spain (2016-2027)
Figure 14 : Diagnosed Population of Endometriosis in Spain (2016-2027)
Figure 15 : Treatable Cases of Endometriosis in Spain (2016-2027)
Figure 16 : Prevalent Cases of Endometriosis in United Kingdom (2016-2027)
Figure 17 : Diagnosed Population of Endometriosis in United Kingdom (2016-2027)
Figure 18 : Treatable Cases of Endometriosis in United Kingdom (2016-2027)
Figure 19 : Prevalent Cases of Endometriosis in Japan (2016-2027)
Figure 20 : Diagnosed Population of Endometriosis in Japan (2016-2027)
Figure 21 : Treatable Cases of Endometriosis in Japan (2016-2027)
Figure 22 : Elagolix, Clinical Trials by Recruitment status, 2018
Figure 23 : Elagolix, Clinical Trials by Zone, 2018
Figure 24 : Femitra, Clinical Trials by Recruitment status, 2018
Figure 25 : Femitra, Clinical Trials by Zone, 2018
Figure 26 : Total 7 Major Market Size in USD, Million (2016-2027)
Figure 27 : Region wise Market Size) in USD, Million (2016-2027)
Figure 28 : 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 29 : United States Market Size in USD, Million (2016-2027)
Figure 30 : United States Market Size by Therapy in USD, Million (2016-2027)
Figure 31 : Germany Market Size in USD, Million (2016-2027)
Figure 32 : Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 33 : France Market Size in USD, Million (2016-2027)
Figure 34 : France Market Size by Therapy in USD, Million (2016-2027)
Figure 35 : United Kingdom Market Size in USD, Million (2016-2027)
Figure 36 : United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 37 : Spain Market Size in USD, Million (2016-2027)
Figure 38 : Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 39 : Italy Market Size in USD, Million (2016-2027)
Figure 40 : Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 41 : Japan Market Size in USD, Million (2016-2027)
Figure 42 : Japan Market Size by Therapy in USD, Million (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report